Three months ago, Charles River Laboratories announced it would shed its manufacturing unit, which has a focus on cell and gene therapies. And, according to its CEO Birgit Girshick, other companies are likely considering doing the same thing.
Three months ago, Charles River Laboratories announced it would shed its manufacturing unit, which has a focus on cell and gene therapies. And, according to …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Allogene CEO to step down; Agios drug fails key test
Radiopharmaceutical outfit Lantheus mulls potential $7B takeover by Curium: Bloomberg
Continuous Manufacturing Strategies for Scalable mAb Production
Viridian, awaiting FDA decision, taps WuXi Bio in eye drug supply deal
Tata Sons-funded MedTherapy brings contract model for cell and gene therapy to India
It’s a crucial moment for the cell and gene therapy field. At the American Society of Gene & Cell Therapy’s annual meeting,…
David Chang will leave his post after an eight-year run at the cell therapy maker. Elsewhere, a next-generation blood disease…
Early last year, startup iECURE’s experimental gene therapy seemingly cured a baby of a life-threatening genetic disease. But new…
Startup works with leading cell therapy companies to bring robotics manufacturing into the clean room, reducing costs by more…
Chinese companies dominate global gene therapy competition with 48 programs vs 20 in US, targeting expensive Western treatments…
Cell and gene therapy makers met in Rome to discuss the field's outlook in Europe. One main topic of conversation: the FDA.
